Home North Pole Economy Izotropic Unveils “Izoview” Brand for Breast Computed Tomography Platform for Development and Trademark Applications

Izotropic Unveils “Izoview” Brand for Breast Computed Tomography Platform for Development and Trademark Applications


Vancouver, British Columbia – (Newsfile Corp. – February 9, 2021) – Izotropic Company (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic“or the”Society“), a company that markets true 3D breast CT imaging technology dedicated to the early detection, diagnosis and treatment of breast cancer, is pleased to unveil its highly anticipated breast CT platform, the izoview.

Concept rendering image. Not for sale in the United States.

To view an improved version of this graphic, please visit:


The Company enriches its intellectual property portfolio by filing several trademark applications in Canada, the United States and Europe. Protection is ongoing for the recognizable company name, platform device name, and logos.

CEO Robert Thast said: “While the izoview platform is not yet available for sale, we are securing critical foundations around the world that will benefit society and patients for years to come. We will continue to plan for the future and identify opportunities to support the company’s growth plans and to accelerate patient access to breast CT scans. “


To view an improved version of this graphic, please visit:

The word “isotropic” was coined by the principal founder of breast CT and company director, Dr. John M. Boone to describe the technology and has since been adopted by the breast imaging industry. Meaning “uniform in all directions,” isotropic inspired the name of the company and the platform itself, as it reflects the device’s unique 360-degree image acquisition and viewing capabilities.


To view an improved version of this graphic, please visit:

The izoview breast imaging platform will be a whole new experience for patients, radiologists and providers:

The patient places her own breast in the izoview imaging cup. The dignity of the patient is preserved because no degrading manipulation of the breast or painful compression of the breast is required. With a comfortable face-down view, the natural orientation of the breast is maintained, producing more appropriate image outputs.

The izoview imaging equipment under the table then circles the patient’s breast, producing approximately 500 high-resolution images (depending on breast length) in 10 seconds, with a radiation dose comparable to a 2-view mammogram. A true 3D reconstructed image (dataset) is produced in 30 seconds, which a radiologist can then view from any angle like a 3D model, or individually drag the 500 cross-sectional images to better determine size , shape, location and relationship to internal structures of the breast, which is essential for surgical planning, treatment monitoring and treatment administration. When used with a contrast medium in ongoing clinical trials, the izoview can detect lesions and tumors in the range of 3 to 5 mm. Compared to the medium-sized tumor found on the screening mammogram, the izoview may offer breast cancer detection 1 to 1.5 years earlier. Each month, delayed cancer treatment increases the risk of death by 10%.

The izoview offers the possibility of a shorter workflow for suppliers. Faster imaging times create the potential for a 3-fold increase in the number of patients imaged per day, which would reduce wait times for critical breast imaging appointments.


For investor relations inquiries, contact:

Dan Sammartino
Phone: 1-778-962-0234
Email: [email protected]

For general inquiries, contact:

[email protected]

About Izotropic Corporation

Izotropic Corporation markets dedicated breast CT imaging technology for the earlier detection, diagnosis and treatment of breast cancer. Extensive preliminary studies have shown that breast CT scan may be able to consistently detect small breast tumors in the size range of 3-5mm. The median size of breast cancers detected by mammography is approximately 11 mm. Routine detection of 3mm lesions would result in detection 1.5 years earlier than mammography.

The initial indication for the use of breast computed tomography as a diagnostic device has been confirmed. Future business goals include identifying additional indications for use, developing additional accessories and products, all aimed at making breast CT scans an indispensable tool for improving breast cancer outcomes.

Additional information about Izotropic Corporation can be found on its website at izocorp.com and reviewing its profile on SEDAR at sedar.com

Forward-looking statements

This document may contain statements which are “forward-looking statements”, which are based on current estimates, assumptions, projections and expectations of management, activities and knowledge of the market and the economic environment in which it operates. The Company has tried, to the extent possible, to identify such information and statements by using words such as “anticipate”, “believe”, “consider”, “estimate”, “expect”, “have the intention to “,” may “,”, “” predict “,” project “,” target “,” potential “,” will “,” would “,” could “,” should “,” continue “,” contemplate ” and other similar expressions and their derivatives in connection with any discussion of future events, trends or prospects or of future operational or financial performance, although not all forward-looking statements contain these identifying words. not guarantees of performance and involve risks and uncertainties which are difficult to control or predict, and as such they may cause the future results of the business of the company to differ materially from the content and implications of these declaration ons. Forward-looking statements are only relevant as of the date on which they are made, and the company assumes no obligation to update or revise forward-looking statements to reflect new information or the occurrence of future events or circumstances. , unless otherwise stated. by the law. Neither the company nor its shareholders, officers and consultants will be responsible for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of company securities. Nothing in this document should be taken as medical or other advice of any kind.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/74014